{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-035806","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2024-11-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.352568+00:00","generated_at":"2026-05-29T22:01:15.415637+00:00","sec_items":["1.01","5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"NRx Pharmaceuticals appoints Michael Abrams as permanent CFO, base salary $325,000","bullets":["Michael Abrams appointed CFO effective Nov 18, 2024, succeeding interim CFO Richard Narido.","Base salary $325,000; initially 50% until Qualified Financing or Feb 1, 2025.","Granted 50,000 stock options under 2021 Omnibus Incentive Plan, vesting over three years.","Abrams previously CFO at Arch Therapeutics, RiseIT Solutions, and FitLife Brands.","Employment agreement includes non-compete, non-solicitation, and severance provisions."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-035806","json":"https://secwatch.observer/filing/0001437749-24-035806.json","markdown":"https://secwatch.observer/filing/0001437749-24-035806.md","text":"https://secwatch.observer/filing/0001437749-24-035806.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000143774924035806/0001437749-24-035806-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000143774924035806/nrxp20241120_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T22:01:15.415637+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8c17d0ad5c","claim":"Richard Narido changed role as Interim Chief Financial Officer at NRX Pharmaceuticals, Inc..","evidence_excerpt":"Mr. Abrams succeeds Interim Chief Financial Officer Richard Narido, who will continue to support the Company’s financial function and other projects.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000143774924035806/0001437749-24-035806-index.htm","confidence":0.85,"family_label":"Executive change","details":[{"label":"Action","value":"succeeded"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"bca4e72e3d","claim":"Michael Abrams was appointed as Chief Financial Officer at NRX Pharmaceuticals, Inc..","evidence_excerpt":"On November 18, 2024, NRx Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing the appointment of Michael Abrams as the Chief Financial Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000143774924035806/0001437749-24-035806-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}